Becton Dickinson stock holds firm as raised EPS guidance and analyst view support 2026 outlook
Published on 08/31/2026 at 21:34 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Becton, Dickinson and Company (ISIN US0718131099) stock is changing hands in the high-$180s in late August 2026 after the medtech group delivered stronger third-quarter fiscal 2026 results and raised its full-year adjusted EPS guidance.
Per a detailed market overview dated August 31, 2026, Becton Dickinson stock is quoted at $188.67, implying year-to-date performance of 25.88% and placing the shares on a dividend yield of 2.23% based on an annualized forward payout of $4.20.
The same overview highlights that in Q3 FY2026, Becton Dickinson generated revenue of $5.0 billion, up 4.4% versus the prior year period, and delivered adjusted EPS of $3.23, an increase of 4.9% year on year, while raising full-year adjusted EPS guidance to a range of $12.62 to $12.72.
Q3 FY2026 earnings lift guidance and cash generation
A recent earnings-call summary for Q3 FY2026, as reflected in a stock-quote and fundamentals page on August 31, 2026, shows that Becton Dickinson reported Q3 FY2026 revenue of $4.98 billion and earnings of $377 million, implying a profit margin of 7.57% for the quarter.
The same Q3 FY2026 snapshot indicates that normalized adjusted EPS reached $3.23 versus a consensus estimate of $3.14, meaning Becton Dickinson exceeded the EPS estimate by $0.09 and delivered mid-single-digit growth in adjusted earnings per share in the period.
In aggregate, the recent coverage of Q3 FY2026 emphasizes that Becton Dickinson has raised full-year fiscal 2026 adjusted diluted EPS guidance, now targeting a range of $12.52 to $12.72, with one detailed medtech stock feature highlighting a slightly narrower raised band of $12.62 to $12.72 after the first full quarter of the reshaped “new BD”.
Alongside the earnings beat and guidance revision, the same medtech stock analysis notes that year-to-date free cash flow reached $1.7 billion, representing an increase of 45% compared with the prior year period, underscoring Becton Dickinson’s ability to convert earnings into cash in fiscal 2026.
Management commentary in that overview points out that the company returned $3.1 billion to shareholders year to date, including $2.3 billion deployed into share repurchases and $0.9 billion distributed through dividends, and reiterated a long-term ambition for 90% free cash flow conversion over time.
Analyst price-target hike and valuation context
The earnings momentum and higher guidance have been mirrored by moves in the analyst community in late August 2026.
A same-day analyst-rating digest dated August 31, 2026 reports that an analyst at BofA Securities maintains a hold recommendation on Becton Dickinson stock and lifts the 12-month price target from $185 to $200, signaling confidence that earnings and cash flow can support modest further upside from current levels.
A European market-data and research page on August 31, 2026 shows Becton Dickinson shares trading at $188.42 in intraday action, with a recent closing price of $189.52 and an average price target across covering analysts of $195.67, implying a gap of 3.24% between the current level and the average target.
The same overview indicates that Becton Dickinson’s dividend profile is backed by trailing EPS of $5.82 covering a trailing dividend payout of $4.19, and notes that the forward price-to-earnings multiple of 14 on the stock is the lowest within a peer group of dividend-raising healthcare names highlighted in the article.
Meanwhile, a separate investing feature dated August 31, 2026 recalls that a recommendation made two months earlier on Becton Dickinson was reported as being up 33% at the time of the call, reinforcing the narrative that the “new BD” restructuring and medtech orientation have been rewarded by the equity market in 2026.
Spinoff and the “new BD” operating profile
The recent medtech stock commentary emphasizes that fiscal 2026 marks the first full quarter for Becton Dickinson operating as the more focused “new BD” following a February 2026 spinoff of its Biosciences and Diagnostics businesses.
By shedding those units, Becton Dickinson has sharpened its focus on core medical technologies such as medication management solutions, infection prevention, surgical devices, and interventional products, and the Q3 FY2026 numbers suggest that the streamlined portfolio is delivering steady growth despite macroeconomic and healthcare budgeting headwinds.
The Q3 FY2026 revenue growth of 4.4% and adjusted EPS increase of 4.9%, together with the raised full-year EPS guidance band and stronger free cash flow, form the backbone of the bull case presented in the late-August medtech analysis.
For investors, the incremental EPS guidance increase to a midpoint near $12.67 for fiscal 2026 versus prior guidance cited in the Q3 earnings-call summary, and the 45% year-on-year free cash flow growth to $1.7 billion, are key datapoints supporting the view that Becton Dickinson can sustain dividend growth and share repurchases while investing in its medtech pipeline.
The same commentary underscores that the dividend stepped up to $1.05 per quarter in 2026, translating into an annualized forward payout of $4.20, which at the late-August 2026 share price of $188.67 yields 2.23% and remains covered by both trailing EPS and management’s free cash flow targets.
Product spotlight: BD Alaris infusion system
One representative product within Becton Dickinson’s medical technology portfolio is the BD Alaris infusion system, a modular intravenous infusion platform used across hospitals and acute-care settings to deliver medications and fluids with integrated safety features.
Market-oriented product material describes the BD Alaris system as combining infusion pumps, guardrails software, and connectivity solutions to help reduce medication errors, standardize dosing across clinical pathways, and feed data into hospital information systems for quality and utilization reporting.
The platform’s ability to link large fleets of devices, support interoperability with electronic medical records, and provide analytics on infusion practice plays into Becton Dickinson’s broader strategy of leveraging hardware, software, and data to improve medication management and patient safety.
For medtech investors monitoring Becton Dickinson stock, the BD Alaris infusion system exemplifies how the company’s installed base and recurring revenue streams in medication delivery and management can underpin longer-term growth beyond the fiscal 2026 guidance band now in place.
Shares trade in the high-$180s heading into September 2026
As of August 31, 2026, Becton Dickinson stock is reported at $188.67, placing the shares within a relatively tight range around a recent closing price of $189.52 on the New York Stock Exchange and reflecting a year-to-date gain of 25.88%.
This late-August 2026 price level keeps the implied dividend yield at 2.23% based on the annualized $4.20 payout and situates the valuation at a forward P/E of 14, which recent medtech coverage characterizes as inexpensive relative to certain healthcare peers that have also raised dividends through multiple economic cycles.
